{"id":309,"date":"2026-02-18T16:25:17","date_gmt":"2026-02-18T14:25:17","guid":{"rendered":"http:\/\/example.test\/?post_type=product&#038;p=309"},"modified":"2026-07-21T11:15:52","modified_gmt":"2026-07-21T08:15:52","slug":"tirzepatide-10-mg","status":"publish","type":"product","link":"https:\/\/life-peptide.com\/es\/product\/tirzepatide-10-mg\/","title":{"rendered":"Tirzepatide 10 mg"},"content":{"rendered":"<p>Tirzepatide is a research-grade dual incretin agonist supplied in lyophilised form for laboratory use. It acts on <strong>both GLP-1 and GIP receptors<\/strong> and has become a central reference compound in metabolic research, especially in models of <strong>appetite regulation, body-weight change, glycaemic control and incretin signalling<\/strong>.<\/p>\n<p>Tirzepatide belongs to a newer class of investigational metabolic peptides designed to engage <strong>more than one incretin pathway at the same time<\/strong>, rather than targeting GLP-1 alone. This dual-receptor profile makes it especially relevant in research focused on obesity, glucose homeostasis, insulin signalling, energy balance and next-generation metabolic therapeutics. Tirzepatide is supplied as a lyophilised vial for laboratory and analytical use only.<\/p>\n<h4><strong>What is Tirzepatide?<\/strong><\/h4>\n<p>Tirzepatide is an investigational <strong>dual incretin receptor agonist<\/strong> designed to activate two key receptor systems involved in metabolic regulation:<\/p>\n<ul>\n<li><strong>Receptor GLP-1<\/strong><\/li>\n<li><strong>Receptor GIP<\/strong><\/li>\n<\/ul>\n<p>This receptor profile places Tirzepatide between <a href=\"https:\/\/life-peptide.com\/es\/product\/semaglutide-10-mg\/\">Semaglutida <\/a>y <a href=\"https:\/\/life-peptide.com\/es\/product\/retatrutide-10-mg\/\">Retatrutida<\/a> in mechanistic breadth. Semaglutide primarily targets GLP-1 alone, while Retatrutide extends beyond GLP-1\/GIP into <strong>agonismo del receptor de glucag\u00f3n<\/strong>. Tirzepatide occupies the middle ground: broader than classical GLP-1 analogues, but more selective than triple agonists.<\/p>\n<p>Because of that positioning, Tirzepatide has become one of the most important benchmark compounds in current metabolic research. It is widely used as a comparison point in studies examining <strong>single-, dual- and triple-receptor incretin strategies<\/strong>. Lilly and peer-reviewed clinical literature consistently describe Tirzepatide as a <strong>once-weekly dual GIP\/GLP-1 receptor agonist<\/strong> with strong effects on glycaemic and body-weight outcomes in human studies.<\/p>\n<h4><strong>Why Tirzepatide matters in metabolic research<\/strong><\/h4>\n<p>Tirzepatide is important because it combines GLP-1 signalling with GIP receptor activity, creating a broader incretin profile than GLP-1 agonists alone while remaining more focused than triple agonists such as Retatrutide.<\/p>\n<p>In the literature, Tirzepatide has been studied in relation to:<\/p>\n<ul>\n<li>regulaci\u00f3n del peso corporal y se\u00f1alizaci\u00f3n del apetito<\/li>\n<li>metabolismo de la glucosa y marcadores gluc\u00e9micos<\/li>\n<li>insulin signalling and nutrient handling<\/li>\n<li>energy balance and systemic metabolic regulation<\/li>\n<li>comparative incretin research across GLP-1, dual agonist and triple agonist models<\/li>\n<\/ul>\n<p>For researchers building a metabolic peptide panel, Tirzepatide often serves as the central comparator molecule between Semaglutide and Retatrutide. It is one of the clearest examples of how expanding from a single-pathway GLP-1 agonist to a dual incretin agonist can change the metabolic profile under investigation. Your current page already points in this direction; the difference here is that we\u2019re making the comparison logic and search surface much more explicit.<\/p>\n<h4><strong>How Tirzepatide works<\/strong><\/h4>\n<p>Tirzepatide is designed to activate two receptor systems involved in metabolic control.<\/p>\n<p><strong>Actividad del receptor GLP-1<\/strong><\/p>\n<p>La se\u00f1alizaci\u00f3n del GLP-1 se asocia con la reducci\u00f3n del apetito, el retraso del vaciamiento g\u00e1strico y el soporte de insulina dependiente de la glucosa. Esta es la v\u00eda que la mayor\u00eda de los investigadores ya conocen de compuestos como la Semaglutida.<\/p>\n<p><strong>Actividad del receptor GIP<\/strong><\/p>\n<p>GIP signalling is thought to influence insulin secretion, nutrient handling, adipose metabolism and the overall incretin response to food intake. In dual-agonist research, GIP activity is one of the major reasons Tirzepatide is mechanistically broader than GLP-1-only compounds.<\/p>\n<p><strong>Dual incretin profile<\/strong><\/p>\n<p>The combination of GLP-1 and GIP activity gives Tirzepatide a different metabolic profile from both Semaglutide and Retatrutide. Compared with Semaglutide, it expands the signalling scope beyond GLP-1 alone. Compared with Retatrutide, it remains more selective because it does not include glucagon receptor agonism.<\/p>\n<p>That makes Tirzepatide particularly useful in research focused on:<\/p>\n<ul>\n<li><strong>GLP-1 vs dual agonist comparisons<\/strong><\/li>\n<li><strong>body-weight and appetite outcomes<\/strong><\/li>\n<li><strong>glucose homeostasis and insulin dynamics<\/strong><\/li>\n<li><strong>the transition from single-pathway to multi-pathway incretin modulation<\/strong><\/li>\n<\/ul>\n<h4><strong>Published clinical findings on Tirzepatide<\/strong><\/h4>\n<p>Tirzepatide has become one of the most closely followed metabolic peptides because published human studies have reported <strong>substantial effects on body weight, glycaemic control and broader cardiometabolic markers<\/strong>. In the SURMOUNT-1 trial published in the <em>New England Journal of Medicine<\/em>, once-weekly Tirzepatide produced <strong>dose-dependent reductions in body weight<\/strong> over 72 weeks in adults with obesity or overweight, with the highest-dose arm showing some of the strongest weight-loss outcomes reported at the time for an incretin-based therapy.<\/p>\n<p>Tirzepatide has also shown strong glycaemic effects in type 2 diabetes research. In SURPASS-2, Tirzepatide was compared directly with once-weekly Semaglutide and demonstrated <strong>greater HbA1c reduction and greater weight reduction<\/strong> across the studied dose arms. Additional SURPASS studies have further established Tirzepatide as one of the key dual agonists in the current metabolic literature. Your current page already cites the most important trials \u2014 SURMOUNT-1, SURPASS-2 and related diabetes work \u2014 which is exactly the right evidence base for this section.<\/p>\n<p>Taken together, these trials are the main reason Tirzepatide is so often used as a reference point in modern obesity and diabetes research. It sits at the centre of the comparison between <strong>GLP-1 agonists, dual GLP-1\/GIP agonists, and newer triple agonist<\/strong> approaches.<\/p>\n<h4><strong>Resultados publicados de seguridad y tolerabilidad<\/strong><\/h4>\n<p>Published clinical studies on Tirzepatide indicate that the most commonly reported adverse events are gastrointestinal, especially <strong>nausea, diarrhoea, decreased appetite, vomiting and constipation<\/strong>. As with other incretin-based agents, these events were generally more common than with placebo and were often <strong>relacionado con la dosis<\/strong>, particularly during the dose-escalation phase of treatment.<\/p>\n<p>Across the major clinical programs, most gastrointestinal events were described as <strong>leve a moderado<\/strong> in severity, and discontinuation rates were still an important part of how Tirzepatide\u2019s overall profile was evaluated. This is one of the reasons published Tirzepatide research is typically discussed not only in terms of efficacy, but also in terms of <strong>tolerabilidad durante la escalada<\/strong>, GI event burden and the balance between metabolic benefit and dropout risk.<\/p>\n<p>This section summarises <strong>published findings on investigational and clinical Tirzepatide research<\/strong>, not instructions or expectations for use of this product.<\/p>\n<h4><strong>Published dosing schedules used in Tirzepatide research<\/strong><\/h4>\n<p>Published Tirzepatide studies generally used <strong>once-weekly administration with stepwise dose escalation<\/strong> rather than starting at the final target dose immediately. In the major obesity and diabetes trials, Tirzepatide was typically studied at <strong>5 mg, 10 mg and 15 mg maintenance doses<\/strong>, with escalation from a lower starting dose over a period of weeks to improve tolerability. Your current reference list already points to the core trials that established this structure.<\/p>\n<p>In practical terms, the published research design for Tirzepatide is important because it shows that <strong>efficacy and tolerability were studied together<\/strong>. Researchers did not simply test \u201cone Tirzepatide dose\u201d; they tested staged escalation strategies leading to different maintenance doses. That is one of the reasons Tirzepatide remains such a useful comparator compound in metabolic peptide research.<\/p>\n<p><strong>Example of the maintenance-dose structure commonly used in major trials<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Published study context<\/th>\n<th align=\"right\">Initial dosing approach in the trial<\/th>\n<th align=\"right\">Maintenance dose arms studied<\/th>\n<th align=\"right\">Frecuencia<\/th>\n<th align=\"right\">Duration<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Obesity \/ diabetes clinical trials<\/td>\n<td align=\"right\">stepwise escalation from lower starting dose<\/td>\n<td align=\"right\">5 mg<\/td>\n<td align=\"right\">una vez por semana<\/td>\n<td align=\"right\">varied by trial<\/td>\n<\/tr>\n<tr>\n<td>Obesity \/ diabetes clinical trials<\/td>\n<td align=\"right\">stepwise escalation from lower starting dose<\/td>\n<td align=\"right\">10 mg<\/td>\n<td align=\"right\">una vez por semana<\/td>\n<td align=\"right\">varied by trial<\/td>\n<\/tr>\n<tr>\n<td>Obesity \/ diabetes clinical trials<\/td>\n<td align=\"right\">stepwise escalation from lower starting dose<\/td>\n<td align=\"right\">15 mg<\/td>\n<td align=\"right\">una vez por semana<\/td>\n<td align=\"right\">varied by trial<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Estos esquemas se incluyen como un resumen del dise\u00f1o de investigaci\u00f3n publicado y no como instrucciones para el uso de este producto.<\/strong><\/p>\n<h4><strong>Tirzepatide vs Semaglutide vs Retatrutide<\/strong><\/h4>\n<p>Researchers often compare these three compounds because they sit on the same metabolic spectrum, but they are not interchangeable.<\/p>\n<p><strong>Tirzepatida<\/strong><\/p>\n<ul>\n<li><strong>Agonista dual<\/strong>GLP-1 + GIP<\/li>\n<li>Central benchmark for dual incretin research<\/li>\n<li>A menudo se discute en relaci\u00f3n con <strong>body-weight outcomes, glycaemic control and incretin signalling<\/strong><\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/life-peptide.com\/es\/product\/semaglutide-10-mg\/\">Semaglutida<\/a><\/strong><\/p>\n<ul>\n<li><strong>Agonista \u00fanico<\/strong>GLP-1<\/li>\n<li>More selective and mechanistically narrower<\/li>\n<li>Punto de referencia com\u00fan para <strong>Investigaci\u00f3n sobre la v\u00eda del GLP-1<\/strong><\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/life-peptide.com\/es\/product\/retatrutide-10-mg\/\">Retatrutida<\/a><\/strong><\/p>\n<ul>\n<li><strong>Agonista triple<\/strong>: GLP-1 + GIP + glucag\u00f3n<\/li>\n<li>Broader receptor profile than Tirzepatide<\/li>\n<li>A menudo se discute en relaci\u00f3n con <strong>weight loss, energy expenditure and next-generation multi-pathway metabolic modulation<\/strong><\/li>\n<\/ul>\n<p>For researchers comparing incretin classes, Tirzepatide often functions as the <strong>middle reference point<\/strong> between single-pathway GLP-1 agonists and broader triple-agonist designs.<\/p>\n<h4><strong>Caracter\u00edsticas del producto<\/strong><\/h4>\n<p>Aplicaci\u00f3n: investigaci\u00f3n de laboratorio y an\u00e1lisis<br \/>\nUso restringido: no apto para consumo humano; no apto para uso m\u00e9dico, veterinario o cosm\u00e9tico<br \/>\nProducido en instalaciones que cumplen con GMP bajo estrictos protocolos de control de calidad.<br \/>\nCada lote se somete a pruebas de laboratorio exhaustivas despu\u00e9s de la producci\u00f3n (puede encontrar el Certificado de An\u00e1lisis debajo de las im\u00e1genes del producto).<br \/>\nLiofilizado (liofilizado) para m\u00e1xima estabilidad y vida \u00fatil prolongada.<br \/>\nSellado en viales est\u00e9riles, listo para la reconstituci\u00f3n.<br \/>\nPurity: \u226599% (HPLC-tested)<br \/>\nAppearance: Lyophilized white\/off-white powder<br \/>\nF\u00f3rmula molecular: C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub><br \/>\nMolecular weight: 4813.45<br \/>\nSequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-\u03b3-Glu-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2<br \/>\n<strong>Almacenamiento<\/strong>: los viales liofilizados sin abrir se almacenan mejor <strong>refrigerar a 2\u20138 \u00b0C<\/strong>, que es el m\u00e9todo de almacenamiento confirmado por nuestro socio de fabricaci\u00f3n y adecuado para hasta 24 meses. Se prefiere la refrigeraci\u00f3n porque minimiza los ciclos innecesarios de congelaci\u00f3n y descongelaci\u00f3n durante la manipulaci\u00f3n rutinaria. Si se requiere un almacenamiento a m\u00e1s largo plazo, los viales liofilizados sin abrir tambi\u00e9n pueden mantenerse congelados. Una vez reconstituidos, almacene siempre a 2\u20138 \u00b0C y no congele.<\/p>\n<h4><strong>Verificaci\u00f3n independiente por terceros<\/strong><\/h4>\n<p>Este lote ha sido sometido a una verificaci\u00f3n anal\u00edtica adicional por parte de terceros a trav\u00e9s de Janoshik Analytical<br \/>\nBatch: TR10-260423<br \/>\nInternal HPLC purity: 99.13%<br \/>\nThird-party verification: 99.62% independently confirmed high purity and identity consistency. <a href=\"https:\/\/verify.janoshik.com\/tests\/166500-Tirzepatide_HZQXE7RE4JKV\" target=\"_blank\" rel=\"noopener\">Verificar terceros<\/a>.<\/p>\n<h4><strong>Reconstituci\u00f3n y manipulaci\u00f3n<\/strong><\/h4>\n<p>Tirzepatide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with <a href=\"https:\/\/life-peptide.com\/es\/product\/bac-10-ml\/\">agua bacteriost\u00e1tica<\/a> Antes de usar. Los p\u00e9ptidos de la clase GLP-1 a veces tardan en disolverse y requieren una reconstituci\u00f3n muy suave para evitar la formaci\u00f3n de espuma o que queden ligeramente turbios.<\/p>\n<p>Para otras gu\u00edas sobre selecci\u00f3n de solventes, planificaci\u00f3n de concentraciones y almacenamiento, consulte el completo <a href=\"https:\/\/life-peptide.com\/es\/reconstitution-of-peptides\/\">Gu\u00eda de Reconstituci\u00f3n de P\u00e9ptidos<\/a> y <a href=\"https:\/\/life-peptide.com\/es\/calculator\/\">Calculadora de Reconstituci\u00f3n<\/a>.<\/p>\n<h4>Referencias de investigaci\u00f3n seleccionadas<\/h4>\n<ul>\n<li>Jastreboff AM et al. <em>\u201cTirzepatide Once Weekly for the Treatment of Obesity.\u201d New England Journal of Medicine<\/em>, 2022.<\/li>\n<li>Frias JP et al. <em>\u201cTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.\u201d New England Journal of Medicine<\/em>, 2021.<\/li>\n<li>Ludvik B et al. <em>\u201cOnce-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin.\u201d The Lancet<\/em>, 2021.<\/li>\n<li>Coskun T y cols. <em>\u201cLY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.\u201d Molecular Metabolism,<\/em> 2018.<\/li>\n<\/ul>\n<h4><strong>Preguntas frecuentes<\/strong><\/h4>\n<p><strong>What kind of peptide is Tirzepatide?<\/strong><\/p>\n<p>Tirzepatide is an investigational dual incretin agonist designed to activate GLP-1 and GIP receptors.<\/p>\n<p><strong>How is Tirzepatide different from Semaglutide?<\/strong><\/p>\n<p>Semaglutide primarily targets GLP-1 alone, while Tirzepatide combines GLP-1 and GIP receptor activity, giving it a broader incretin signalling profile.<\/p>\n<p><strong>How is Tirzepatide different from Retatrutide?<\/strong><\/p>\n<p>Retatrutide is a triple agonist that adds glucagon receptor activity to the GLP-1\/GIP profile. Tirzepatide remains more selective as a dual GLP-1\/GIP agonist.<\/p>\n<p><strong>What research areas is Tirzepatide associated with?<\/strong><\/p>\n<p>Tirzepatide has been studied in the literature in relation to body-weight outcomes, appetite regulation, glycaemic control, insulin signalling and incretin biology.<\/p>\n<p><strong>\u00bfEst\u00e1 este producto destinado al uso humano?<\/strong><\/p>\n<p>No. Este producto se suministra estrictamente para uso en investigaci\u00f3n \u00fanicamente y no est\u00e1 destinado al consumo humano ni a uso terap\u00e9utico.<\/p>\n<h4><strong>Contexto de investigaci\u00f3n relacionado<\/strong><\/h4>\n<p>Tirzepatide is part of the dual incretin receptor agonist (GLP-1\/GIP) metabolic research class. For mechanistic comparison with single-pathway GLP-1 agonists and triple-agonist compounds, see our <strong><a href=\"http:\/\/example.test\/glp-1-metabolic-research-guide\/\" target=\"_blank\" rel=\"noopener\">Gu\u00eda de investigaci\u00f3n metab\u00f3lica de GLP-1<\/a>.<\/strong><\/p>\n<p>Explorar todos los compuestos en el <a href=\"\/es\/product-category\/metabolic-research\/\"><strong>Categor\u00eda de investigaci\u00f3n metab\u00f3lica.<\/strong><\/a><\/p>\n<p>Los investigadores que comparan la activaci\u00f3n de m\u00faltiples receptores tambi\u00e9n pueden examinar:<\/p>\n<ul>\n<li data-start=\"2635\" data-end=\"2671\"><a href=\"http:\/\/example.test\/product\/retatrutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Retatrutide (GLP-1\/GIP\/glucagon triple-receptor agonist)<\/a><\/li>\n<li data-start=\"2674\" data-end=\"2702\"><a href=\"http:\/\/example.test\/product\/semaglutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Semaglutida (agonista del receptor GLP-1)<\/a><\/li>\n<\/ul>\n<p><strong>NOTE:<\/strong> This is for educational reference only and does not constitute medical advice.<\/p>\n<p><strong>Disclaimer:<\/strong><br \/>\nEste producto se vende \u00fanicamente para fines de investigaci\u00f3n. No est\u00e1 destinado a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. El comprador asume toda la responsabilidad por su manipulaci\u00f3n y uso adecuados.<\/p>","protected":false},"excerpt":{"rendered":"<p>Tirzepatide is a research-grade dual incretin agonist supplied in lyophilised form for laboratory use. It acts on both GLP-1 and GIP receptors and has become a central reference compound in metabolic research, especially in models of appetite regulation, body-weight change, glycaemic control and incretin signalling.<\/p>\n<p>||<\/p>\n<p>Pureza \u226599% | Env\u00edos a la UE a partir de 5 \u20ac | Posibilidad de elegir env\u00edo gratuito | Se aceptan pagos con tarjeta<\/p>","protected":false},"featured_media":1247,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[19],"product_tag":[257,144,279,139,250,251,247,258,252,246],"class_list":["post-309","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic-research-peptides","product_tag-appetite-regulation","product_tag-dual-agonist","product_tag-fat-loss-peptide","product_tag-glp-1-research","product_tag-glp-1-gip-agonist","product_tag-glucose-research","product_tag-metabolic-peptide","product_tag-obesity-peptide","product_tag-obesity-research","product_tag-weight-loss-peptide","first","instock","taxable","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product\/309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/comments?post=309"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/media\/1247"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/media?parent=309"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product_brand?post=309"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product_cat?post=309"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product_tag?post=309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}